EcoDrugPlus

Uncharacterized Loc114860227

Ensembl ID : ENSBSLG00000002844
Gene Symbol: LOC114860227
2 Cross references
194 Possible Orthologues:

Urotensin 2 Receptor

Ensembl ID : ENSBSLG00000022079
Gene Symbol: UTS2R
1 Cross references
92 Possible Orthologues:

Utrophin

Ensembl ID : ENSBSLG00000024333
Gene Symbol: UTRN
3 Cross references
254 Possible Orthologues:

Vascular Endothelial Growth Factor A

Ensembl ID : ENSBSLG00000015203
Gene Symbol: VEGFA
3 Cross references
197 Possible Orthologues:

Vascular Endothelial Growth Factor A-A-Like

Ensembl ID : ENSBSLG00000022835
Gene Symbol: LOC114842808
3 Cross references
180 Possible Orthologues:

Venom Prothrombin Activator Porpharin-D-Like

Ensembl ID : ENSBSLG00000001367
Gene Symbol: LOC114851169
3 Cross references
246 Possible Orthologues:

Vitamin D Receptor

Ensembl ID : ENSBSLG00000024855
Gene Symbol: VDR
3 Cross references
392 Possible Orthologues:

Vitamin D3 Receptor B

Ensembl ID : ENSBSLG00000002180
Gene Symbol: LOC114855551
3 Cross references
394 Possible Orthologues:

Vitamin K Epoxide Reductase Complex Subunit 1-Like Protein 1

Ensembl ID : ENSBSLG00000014348
Gene Symbol: LOC114845530
3 Cross references
191 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Alpha-1c-Like

Ensembl ID : ENSBSLG00000024311
Gene Symbol: LOC114862070
3 Cross references
215 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Alpha-1d-Like

Ensembl ID : ENSBSLG00000001021
Gene Symbol: LOC114855133
3 Cross references
212 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Beta-4-Like

Ensembl ID : ENSBSLG00000013440
Gene Symbol: LOC114858622
3 Cross references
203 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).